Ultimately, the lack of treatment effect observed in the FXLEARN trial, combined with previous negative trials, provides conclusive evidence that reduction of mGluR5 activity is not beneficial for the treatment of cognition and behavior in people with FXS. The gene discussed is GRM5; the disease is fragile X syndrome.